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with normal ACSF containing the following (in mM): 125 NaCl, 2.4 KCl, 1.2 NaH 2 PO 4 , 25 NaHCO 3 , 25 glucose, 2 CaCl 2 , and 1 MgCl 2 . Solution were equilibrated with 95 % O 2 and 5 % CO 2 throughout the experiment.
Electrophysiological recording
Patch-clamp recordings were made from visually identified CA1 pyramidal neurons in the hippocampus. Recording electrodes had tip resistances of 3 -5 MΩ when filled with internal recording solution containing the following (in mM): 135 CsCl, 20 HEPES, 2 EGTA, 2 Mg-ATP, 0.5 Na-GTP, and 10 QX-314 (pH 7.25) . Monopolar extracellular stimulating electrodes were filled with ACSF and placed in the border of stratum radiatum (SR) and lacnosum moleculare (LM) or in stratum pyramidale (SP) to evoke distal or perisomatic synaptic responses, respectively (Prenosil et al., 2006; Jurgensen and Castillo, 2015) . After forming the whole cell configuration, CA1 pyramidal neurons were voltage clamped at -70 mV. Inhibitory postsynaptic currents (IPSCs) were isolated by the inclusion of CNQX (10 μM) and D-APV (50 μM) in the extracellular solution. Miniature IPSCs (mIPSCs) were recorded in the presence of tetrodotoxin (TTX) (1 μM). To record asynchronous IPSCs (aIPSCs), the normal recording ACSF was exchanged for strontium-ACSF containing the following (in mM): 125 NaCl, 2.4 KCl, 1.2 NaH 2 PO 4 , 25 NaHCO 3 , 25 glucose, 6 SrCl 2 , 0.5 CaCl 2 , and 2 MgCl 2 . Stimuli were given through the extracellular stimulating electrodes placed in SP. Recorded aIPSCs were analyzed within a window from 50 ms to 500 ms after the stimulus artifact (Fernandes et al., 2015) . Rise time was measured as the time from the onset of the inward current to the peak. Decay time was defined as the time from the peak to 37 % of the amplitude of the responses. Recordings were discarded when the access resistance (R a ) showed > 20 % change during the recording. Data were collected and analyzed using pClamp 10 software (Molecular Devices) and Mini Analysis software (Synaptosoft).
In vivo pharmacology and behavioral analysis
Male and female P18 -P20 F1.Scn1a +/mice were orally administered (gavage) 10, 17.8 or 31.6 mg/kg AZD7325 (generously provided by AstraZeneca, Inc.) or vehicle (5% 2-hydroxypropyl-β-cyclodextrin (HPBCD) (Acros Organics, New Jersey, USA)) 30 minutes prior to the induction of hyperthermia. Core body temperature was monitored using a RET-3 rectal temperature probe (Physitemp Instruments, Inc, New Jersey, USA) and controlled by a heat lamp connected to a rodent temperature regulator (TCAT-2DF, Physitemp) reconfigured with a Partlow 1160+ controller (West Control Solutions, Brighton, UK) as described previously . Body temperature was raised by 0.5 °C every two minutes until the onset of the first clonic convulsion with loss of posture. Once body temperature reached 42.5°C, the heat lamp was turned off and mice remained in the chamber until a generalized tonic-clonic seizure (GTCS) occurred or 3 minutes elapsed. Mice that did not experience a GTCS during the 3-minute hold were considered seizure-free.
Introduction
Despite advances in the development of therapies for epilepsy, approximately 40% of patients have seizures that are refractory to treatment and also suffer from various comorbidities and adverse effects of antiepileptic drugs (AEDs) (Perucca et al., 2009; Brodie, 2017; Manford, 2017) . The GABA A receptor is a target of commonly used AEDs including benzodiazepines (BDZs), barbiturates, and valproate (VPA) (Greenfield, 2013) . GABA A receptors form heteromeric pentamers most typically with a stoichiometry composed by two α, two β, and one γ subunits (Olsen, 2018) . The α 1 and α 2 subunits are amongst the most prevalent subunits present in synaptic GABA A receptors, which participate in rapid phasic inhibition (Olsen and Sieghart, 2008) .
The biological roles of α 1 and α 2 subunits are not fully characterized, however they govern the kinetics of the channel properties of GABA A receptors. Receptors comprised of the α 2 subunit mediate relatively slower decaying inhibitory postsynaptic currents (IPSCs) than those mediated by the most abundant GABA A receptor type which contains α 1 (α 1 β 2 γ 2 ) (Gingrich et al., 1995) (Whiting, 2003) . In vivo, activation of α 1 containing GABA A receptors is implicated in the hypnotic and motor effects of GABA receptor positive allosteric modulators (PAMs), whereas α 2 and α 3 containing receptors have been associated with anxiolytic and pain relieving effects (Low et al., 2000; McKernan et al., 2000; Knabl et al., 2008) . The differential roles of these different receptor types in potentially controlling seizures is not clear, however subunit specific compounds hold promise for the treatment of epilepsies (Whiting, 2003; Rudolph and Knoflach, 2011) .
Dravet Syndrome (DS) is an early onset epileptic encephalopathy (Scheffer et al., 2017; Steel et al., 2017) caused by haploinsufficiency of SCN1A that encodes the voltage-gated sodium channel Na v 1.1 (Brunklaus and Zuberi, 2014; Steel et al., 2017) . As with other monogenic disorders there is considerable evidence that pleiotropic effects of loss of SCN1A gene expression contribute to the phenotype. Particularly, work in a mouse model of DS (Scn1a +/-) has demonstrated that the cellular excitability and epilepsy phenotypes are highly dependent upon the background strain of the mouse (Yu et al., 2006; Miller et al., 2014; Mistry et al., 2014; Rubinstein et al., 2015; , which may be a corollary to the variable clinical severity reported in patients (Mullen and Scheffer, 2009 . These strain-dependent phenotypes have led to the suggestion that modifier genes strongly contribute to the phenotype severity (Mullen and Scheffer, 2009; Miller et al., 2014; Mistry et al., 2014; Rubinstein et al., 2015) . Genetic mapping studies have discovered several candidate genes contributing to the strain-dependent phenotype in mice Calhoun et al., 2017) .
One of the candidate modifier genes, Gabra2, is of particular interest because it encodes for the α 2 subunit of the GABA A receptor . These studies demonstrated higher Gabra2 transcript and protein expression in the 129 protective strain compared to expression in the two strains that are susceptible to the Scn1a mutation, B6 and F1. This strain-dependence of expression of GABA receptor subunits is consistent with previous reports (Mulligan et al., 2012; Yeo et al., 2016) . Moreover, the administration of the 1,5-BDZ clobazam (CLB) is associated with higher temperature threshold for hyperthermia-induced seizure in F1.Scn1a +/mice, which indicates that potentiating GABA A receptors has a strong anti-seizure effect in these mice Hawkins et al., 2017) . This is consistent with CLB and VPA as first-line treatments in DS patients (Wirrell et al., 2017) .
Here we demonstrated that AZD7325, a selective PAM for α 2 / α 3 subunit containing GABA A receptors, preferentially potentiated GABAergic inhibitory postsynaptic currents (IPSCs) in hippocampal perisomatic synapses by prolonging their decay kinetics. There was a strong strain dependent effect of the drug, with a significantly larger effect in the 129 mouse strain than in B6 or F1 strains. These findings are consistent with the interpretation that α 2 GABA receptor subunits are relatively enriched in synapses of mice in the 129 strain. In addition, in vivo administration of AZD7325 was associated with a higher temperature threshold for hyperthermia-induced seizure in Scn1a +/mice without any apparent sedative effect. Our results indicate that the α 2 subunit is critical for seizure pathophysiology in the DS mouse model and targeting α 2 containing receptors with a subunit selective PAM is a potential therapeutic strategy for DS.
Results

AZD7325 is a PAM for native GABA A receptors.
AZD7325, 4-amino-8-(2-fluoro-6-methoxy-phenyl)-N-propyl-cinnoline-3-carboxamide, has been shown to have selectivity for α 2 / α 3 subunits and to potentiate GABA A receptor mediated responses in heterologous expression systems (Alhambra et al., 2011; Saito et al., 2016) . To determine how AZD7325 affects native GABA receptors, we examined the effect of the compound on phasic inhibitory synaptic events in hippocampal slices of wild-type F1 mice. Miniature IPSCs (mIPSCs) were recorded from CA1 pyramidal neurons, before and after the application of vehicle (Veh; DMSO) or AZD7325 (AZD; 100 nM) for ~10 min. AZD7325 treatment did not potentiate the amplitude (Figure 1 a and b ) but significantly prolonged the decay time of mIPSCs (Figure 1 c -e). There was no effect on the frequency and the rise time of mIPSCs after the AZD7325 treatment (Wilcoxon signed-rank test: Frequency: 4.3 ± 0.5 Hz and 4.2 ± 0.4 Hz, p = 0.41; Rise time: 2.4 ± 0.1 ms and 2.5 ± 0.1 ms, p = 0.33; before and after the treatment, respectively; n = 15 cells / 7 mice). These results demonstrate that AZD7325 acts as a PAM for native GABA A receptors by prolonging the decay kinetics of IPSCs in the hippocampus in acute slices.
AZD7325 has differential activity at perisomatic synapses
AZD7325 has been reported to have high affinity for α 2 and α 3 subunits of GABA A receptors (Alhambra et al., 2011; Saito et al., 2016) . In the hippocampus, prior work has demonstrated that GABA A receptor content of inhibitory synapses is spatially distributed along the somato-dendritic length. Synapses close to the soma preferentially contain α 2 GABA A receptor subunits whereas synapses more distal from the soma are dominated by α 1 subunits (Prenosil et al., 2006) . To differentially examine perisomatic and distal synapses, we isolated evoked IPSCs from either population by stimulating inhibitory synaptic input in different layers in the hippocampal slice (Prenosil et al., 2006; Jurgensen and Castillo, 2015) (Figure 2a ). As expected, perisomatically evoked IPSCs had kinetics distinct from the distally evoked synaptic currents, which displayed significantly faster rise times and decay times (Figure 2 b and c). AZD7325 had no effect on the decay kinetics of distal IPSCs (Figure 2 d -f ), whereas the decay kinetics of perisomatic evoked IPSCs were significantly prolonged by AZD7325 application (Figure 2 d -f ). These results demonstrate that the α 2 / α 3 selective PAM differentially modulates inhibitory synapses located in the perisomatic region of CA1 neurons. This finding is consistent with the proposal that there are segregated populations of GABA A receptors at CA1 synapses (Prenosil et al., 2006) . As with mIPSCs, these were no significant effects of AZD7325 on the amplitude of IPSCs in either distal or perisomatic synapses (Wilcoxon signed-rank test: Distal: 216.0 ± 27.0 pA and 197.8 ± 31.1 pA, p = 0.23; Perisomatic: 1034.0 ± 118.6 pA and 913.4 ± 149.5 pA, p = 0.16; before and after the treatment, respectively: n = 10 cells / 5 mice and n = 7 cells / 4 mice, in distal and perisomatic synapses, respectively). In addition, the paired pulse ratio (PPR) measured at an interval of 50 ms was not affected by AZD7325 suggesting that this compound does not have any obvious unintended presynaptic effects ( Figure 2 g & h).
The magnitude of AZD7325 effect is dependent upon the background strain
We and others have previously reported that there is marked strain dependence in the expression levels of the α 2 subunit of GABA A receptors (Mulligan et al., 2012; Yeo et al., 2016) . This strain dependent expression difference is correlated with phenotype severity in the DS mouse model, suggesting that it may contribute to the underlying protective effect from seizures in 129.Scn1a +/mice . We therefore tested whether AZD7325 has a strain dependent effect. AZD7325 significantly prolonged the decay time of mIPSCs recorded from CA1 neurons from mice on the 129 background strain (Figure 3 a -f). The decay time was lengthened by 130.0 ± 3.2 % (n = 13) after AZD7325 treatment in the 129 strain, which was significantly greater than that in B6 (114.4 ± 2.9 %, n = 12) and F1 (117.1 ± 2.8 %, n = 15 : Figure 1 e) (one-way ANOVA : F (2,37) = 7.69, p = 0.003 for B6 vs 129, 0.01 for F1 vs 129) mice ( Figure 3 f ; F1 data not shown in the figure) . These results are consistent with our previous report of differential expression of Gabra2 gene in the 129 strain that confers resistance to seizures in the Scn1a +/-DS model .
Because our local stimulation experiments had demonstrated that AZD7325 is effective only on perisomatic stimulated synapses, we selectively stimulated these whilst also using strontium (Sr 2+ ) replacement to isolate individual synaptic events by desynchronizing release of the compound IPSCs and to record asynchronous IPSCs (aIPSCs) in the perisomatic synapses (Xu-Friedman and Regehr, 2000; Fernandes et al., 2015) . AZD7325 application significantly prolonged the decay time of aIPSCs in the perisomatic synapses in both F1 and 129 strains. However, the effect of AZD7325 on the decay time of aIPSCs was greater in the 129 strain compared to the F1 strain, consistent with a differential expression of the α 2 subunit in inhibitory synapses in these strains (Figure 3 g -j).
AZD7325 modulates IPSCs in Scn1a
+/mice.
Our data indicate that AZD7325 specifically modulates inhibitory currents particularly in perisomatic synapses in the CA1 of the hippocampus and suggest that potentiation of α 2 subunit containing GABA A receptors could be seizure protective in Scn1a +/mice. Therefore, we tested whether AZD7325 modulates hippocampal GABAergic responses in Scn1a +/mice. We first examined the effect of AZD7325 on hippocampal inhibitory synaptic transmission in CA1 neurons in Scn1a +/mice. AZD7325 application prolonged the decay time of mIPSCs in Scn1a +/mice, and as expected the modulation was greater in 129.Scn1a +/mice on the seizure resistant strain than in the seizure susceptible F1.Scn1a +/strain ( Figure   4 a -c). Similarly, AZD7325 significantly prolonged the aIPSC decay time in perisomatic synapses, and consistent with the mIPSC findings, the prolongation of the decay kinetics was stronger in slices from mice on the 129 background (Figure 4 d -f ).
AZD7325 alters the threshold for hyperthermia -induced seizures in Scn1a +/mice.
To directly assess whether in vivo AZD7325 administration affects the seizure threshold in F1.Scn1a +/mice, we used a hyperthermia-induced seizure assay . AZD7325 had a significant protective effect against seizure induction in F1.Scn1a +/mice ( Figure 5 a) . At doses as low as 10 mg/kg, there was a significantly higher threshold temperature for hyperthermia-induced seizures. At higher doses up to 31.6 mg/kg, this effect was sustained but not significantly greater than lower doses (Figure 5 a) . Importantly, no obvious signs of sedation were noted during the hyperthermia assay. To quantify whether the highest dose of AZD7325 was sedating, we tested another cohort of wild-type F1 mice and monitored their activity in an open field assay. Both vehicle and AZD7325 treated mice demonstrated a characteristic habituation of activity during the 60 min monitoring. However, no difference was observed in the total activity or distance traveled between mice in the vehicle and AZD7325 treatment groups, demonstrating no major sedation caused by AZD7325 at this dose ( Figure 5 b -d) . The time spent in the center of the chamber and the number of crossings into the center were indistinguishable between the groups, suggesting AZD7325 did not show an obvious anxiolytic effect in wild-type mice at this dose ( Figure 5 e -f ).
Discussion
In this study, we demonstrated that AZD7325, which has previously been characterized as a PAM selective for recombinant α 2 / α 3 subunits of GABA A receptors (Alhambra et al., 2011) , potentiates hippocampal GABAergic synaptic responses in the CA1, and is protective for hyperthermia induced seizures in the F1.Scn1a +/mice, a mouse model of DS. Moreover, we observed that GABAergic synapses proximal to the somatic region of CA1 neurons are preferentially modulated by AZD7325, suggesting that there is a distributed localization of α 2 / α 3 containing GABA A receptors that might provide a potent inhibitory influence on pyramidal neurons. The results are the first to demonstrate the action of this compound on native receptors in the hippocampus and to provide insight into how it enhances phasic inhibitory transmission, which may contribute to the dampening of seizure activity.
GABA A receptors containing α 2 subunits have a privileged role in hippocampal inhibition
GABA A receptors are formed from heterogeneous assemblies of subunits that are both developmentally and regionally regulated to give diverse expression patterns throughout the brain (Mody and Pearce, 2004) . The α subunits are of particular interest for targeted therapeutics because of the divergence in their activities that segregate the sedative and anesthetic effects mediated by α 1 subunit containing GABA A receptors (Whiting, 2003; Rudolph and Knoflach, 2011) from the anxiolytic and analgesic effects of drugs selectively targeting α 2 / α 3 subunit GABA A receptors. Thus, it is possible that targeting subsets of GABA A receptors containing the α 2 / α 3 subunits could be used to mitigate undesirable sedative and amnesic effects of GABAergic AEDs. Several PAMs selective for the α 2 / α 3 subunits have been developed including L-838,417 (α 1 -sparing PAM) (McKernan et al., 2000; Knabl et al., 2008) , TCS1105 (Taliani et al., 2009 ), AZD7325 (Alhambra et al., 2011; Zhou et al., 2012) , and PF-06372865 (Gurrell et al., 2018; Nickolls et al., 2018) , although none of these are currently in clinical use as an AED. The commonly prescribed AED and anxiolytic medication clobazam (CLB) is a 1,5-BDZ that is known to be metabolized in vivo to active N-desmethyl clobazam (N-CLB) that has modest preference for α 2 / α 3 containing receptors (Ralvenius et al., 2016) (but, also see (Jensen et al., 2014) ).
In direct recordings from CA1 neurons we observed that selective stimulation of perisomatic, but not distal dendritic IPSCs could isolate synapses that were preferentially potentiated by the α 2 / α 3 selective PAM AZD7325. This is consistent with previous reports that demontrated α 1 containing receptors are functionally localized to distal dendritic synapses whereas α 2 containing GABA A receptors preferentially mediate perisomatic phasic inhibition (Prenosil et al., 2006) . Using high resolution EM freeze fracture immunolabeling, it was recently demonstrated that synapses on the soma and axon initial segment (AIS) contain receptors with both α 1 and α 2 subunits (Kerti-Szigeti and Nusser, 2016) . Moreover, prior work had suggested a remarkable input specific molecular segregation of GABA A receptor subunits. Specifically, α 1 containing receptors at synapses formed by paralbumin (PV) positive interneurons (Klausberger et al., 2002) and α 2 containing receptors at synapses formed by cholecystokinin (CCK) positive interneurons (Nusser et al., 1996; Fritschy et al., 1998; Nyiri et al., 2001) may not be so clearly divided. Rather, distinct synapses onto the soma from PV, CCK, and those onto the AIS have similar subunit composition where both α 1 and α 2 subunits are present in most labeled synapses (Kasugai et al., 2010; Kerti-Szigeti and Nusser, 2016) . Our functional results using the selective pharmacological profile of AZD7325 are consistent with inhibitory synapses localized close to the soma containing receptors with the α 2 subunit.
Modulation of GABA A receptors containing α 2 subunits suppresses seizures
GABA A receptor PAMs are known to potentiate IPSCs by increasing the amplitude, as well as prolonging the decay time of the synaptic current (Pawelzik et al., 1999; Thomson et al., 2000; Kang-Park et al., 2004; Xu and Sastry, 2005; Gross et al., 2011) . For instance, diazepam, a nonselective 1,4-BDZ, has been reported to potentiate both the amplitude and decay time of IPSCs in CA1 pyramidal neurons in hippocampal slices (Zhang et al., 1993) . However, there are also examples of GABA A PAMs such as stiripentol and CLB that prolong the decay of the synaptic current, with no effect on amplitude (Quilichini et al., 2006) . Stiripentol selectively enhances the decay of IPSCs by increasing the open time of the receptor-channel (Quilichini et al., 2006) as does 1,4-BDZ derivative midazolam (Otis and Mody, 1992) . GABA A channels are also potentiated by barbiturates, which bind to a site independent of the benzodiazepine binding site and lengthen the mean open times with no effect on open probability (MacDonald et al., 1989) . AZD7325 also prolonged the decay time of the currents without increasing the amplitude of IPSCs. This finding suggests that AZD7325 may prolong the mean open time of α 2 / α 3 containing GABA A receptors similar to barbiturates or other AEDs that bind to the barbiturate site such as stiripentol, which also regulate IPSC decay kinetics without affecting the current amplitude (Zhang et al., 1993; Quilichini et al., 2006) .
Prior work from our laboratory demonstrated that there is a strong strain dependence to the phenotype in the Scn1a +/mouse model of DS. Mice on a congenic 129S6/SvEvTac background are protected from seizures and premature mortality . Fine mapping of the Dravet syndrome modifier 1 (Dsm1) locus identified Gabra2 as a potential candidate modifier gene that is differentially expressed between the seizure-resistant 129 strain and the seizure-susceptible F1 strain ).
Here we directly tested whether synapses known to contain α 2 -GABA A receptors are differentially modulated by AZD7325. The α subunits are known to govern the kinetics of GABA currents (Verdoorn et al., 1990; Lavoie et al., 1997) , however we did not observe any difference in the amplitude or kinetics of mIPSCs between recordings from any of the mouse strains tested (not shown), likely because of the heterogeneous complement of receptors at synapses that contain both α 1 and α 2 receptors, where the α 1 containing receptors govern the kinetics of IPSCs (Panzanelli et al., 2011) . However, the effect of AZD7325 on mIPSC decays was significantly more pronounced in the seizure-resistant 129 strain than in the F1 and B6 seizure-susceptible strains, consistent with elevated abundance of α 2 containing receptors at synapses in 129 strain relative to B6.
While we found a strain dependence of the effects of AZD7325 on mIPSCs, there was no genotype dependent effect in the DS mice. Synaptic currents were potentiated to a similar level in Scn1a +/mice as in wild-type littermates on the same congenic background, and this supports the notion that modifier genes in the background strains are important determinants of the phenotype expressed in DS mice. In addition, in vivo administration of AZD7325 to F1.Scn1a +/mice was associated with higher temperature threshold for hyperthermia-induced seizures in a dose dependent manner with no obvious sedative effect at the highest dose administered. This directly supports the therapeutic potential of α 2 -selective PAMs as effective seizure suppressors. Prior studies have also suggested that α 2 -containing receptors contribute to seizure susceptibility. For instance, rats that are non-responders to typical AEDs after kindling have lower expression of several GABA A receptor subunits including α 2 in the hippocampus compared to kindled rats that are responsive to drug treatment (Bethmann et al., 2008) . In addition, recent work demonstrated that loss of a novel α 2 interacting partner, collybistin, led to lower α 2 expression and loss of GABAergic synapses on the axon initial segment (AIS) along with greater seizure susceptibility (Hines et al., 2018) . Furthermore, in human genetic studies a de novo mutation in the GABRA2 gene that was found in patients with severe epilepsy and developmental delay, has been demonstrated to have lower channel expression and exhibit effects on gating of GABA A receptors (Butler et al., 2018) . Our studies in the Scn1a +/mouse model provide an explanation of how genetic modifiers can affect phenotype penetrance, and further support the importance of considering GABA receptor subunit selective pharmacology for the treatment and suppression of seizures. Wilcoxon signed-rank test: Veh group: 46.5 ± 3.6 pA (Pre) and 44.7 ± 3.7 pA (Veh), p = 0.28, n = 10 cells / 5 mice; AZD group: 44.6 ± 3.0 pA (Pre) and 44.5 ± 2.8 pA (AZD), p = 0.72, n = 15 cells / 7 mice. n.s. denotes p ≥ 0.05. (c) Representative mIPSC traces scaled to the peak before (Pre) and after DMSO (Veh) or AZD7325 (AZD) treatments. Calibration: 20 ms. (d) Grouped data for mIPSC decay time before (Pre) and after DMSO (Veh) or AZD7325 (AZD) treatments. Decay is prolonged after AZD treatment.
Figure Legends
Wilcoxon signed-rank test: Veh group: 9.3 ± 0.5 ms (Pre) and 9.2 ± 0.6 ms (Veh), p = 0.85, n = 10 cells / 5 mice; AZD group : 7.2 ± 0.3 ms (Pre) and 8.4 ± 0.4 ms (AZD), p < 0.01, n = 15 cells / 7 mice. n.s. and * denotes p ≥ 0.05 and < 0.05, respectively. (e) Relative mIPSC decay time before (Pre) and after DMSO (Veh) or AZD7325 (AZD) treatments. (a) Cumulative generalized tonic-clonic seizure (GTCS) incidence curve for F1.Scn1a +/mice treated with AZD7325 (AZD) or vehicle (Veh) and then subjected to hyperthermia-induced seizure threshold testing. All three doses, 10, 17.8 and 31.6 mg/kg significantly shifted the temperature threshold curve for hyperthermia-induced seizures (p < 0.0001). Vehicle treated F1.Scn1a 
